Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNTRY STUDY TO DEMONSTRATE THE EFFICACY OF A SINGLE OF GSK¿S RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS AGED 60 YEARS AND ABOVE

Intervention/treatment:
RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION PROTEIN F3 OLDER ADULT (RSVPREF3 OA) VACCINE (GSK3844766A)
Medical condition:
RESPIRATORY SYNCYTIAL VIRUS
Protocol code:
212494 (RSV OA=ADJ-006)
Control number:
251261
Status:
Closed
Approved:
May 12, 2021
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT04886596
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
60 Years and older
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
GSK Response Center
Organization
GlaxoSmithKline
Phone:
866-435-7343
Sponsor
GLAXOSMITHKLINE INC

Locations

Alberta

GSK Investigational Site
Edmonton, Alberta, T5A 4L8

British Columbia

GSK Investigational Site
New Westminster, British Columbia, V3L 3W4
GSK Investigational Site
Surrey, British Columbia, V3S 2N6
GSK Investigational Site
Vancouver, British Columbia, V6Z 2T1
GSK Investigational Site
Victoria, British Columbia, V8V 3M9
GSK Investigational Site
Victoria, British Columbia, V8V 4A1

Nova Scotia

GSK Investigational Site
Halifax, Nova Scotia, B3J 3G9
GSK Investigational Site
Truro, Nova Scotia, B2N 1L2

Ontario

GSK Investigational Site
Greater Sudbury, Ontario, P3C 1X3
GSK Investigational Site
London-Ontario, Ontario, N5W 6A2
GSK Investigational Site
Ottawa, Ontario, K1H 8L6
GSK Investigational Site
Sarnia, Ontario, N7T 4X3
GSK Investigational Site
Toronto, Ontario, M9W 4L6

Quebec

GSK Investigational Site
Chicoutimi, Quebec, G7H 7Y8
GSK Investigational Site
Mirabel, Quebec, J7J 2K8
GSK Investigational Site
Pointe-Claire, Quebec, H9R 4S3
GSK Investigational Site
Québec, Quebec, G1W 4R4
GSK Investigational Site
Saint-Charles-Borromée, Quebec, J6E 2B4
GSK Investigational Site
Sainte-Foy, Quebec, G1E 7G9
GSK Investigational Site
Sherbrooke, Quebec, J1J 2G2

Results

See the results from the trial NCT04886596. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?